Akashi Therapeutics is a clinical stage biotechnology company developing a portfolio of products for Duchenne muscular dystrophy and other rare diseases. The lead clinical asset is HT-100, and drug candidate with potent anti-inflammatory and anti-fibrotic properties that also promotes healthy muscle regeneration. The company's second clinical candidate is DT-200, a Selective Androgen Receptor Modulator (SARM), targeted to build muscle mass and strength.
Akashi is a combination of Halo Therapeutics and Dart Therapeutics, two companies founded as a collaboration between patient advocacy organizations and biotechnology industry veterans. Akashi is lead by a team of experienced drug developers.
Company Details
- Employees
- 3
- Founded
- -
- Address
- Cambridge, Ma
- Phone
- 617-431-7250
- IN****@****TRX.COM
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- akashirx.com
- Keywords
- Chanhassen.
- HQ
- Cambridge, MA
Akashi Therapeutics, Inc. Questions
Akashi Therapeutics, Inc.'s helpline number is 617-431-7250
Akashi Therapeutics, Inc.'s website is akashirx.com
Akashi Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/akashi-therapeutics-inc-
Akashi Therapeutics, Inc. has
3 employees.
View email and phone details for 3
employees at Akashi Therapeutics, Inc..
Akashi Therapeutics, Inc.'s industry is
Biotechnology Research
Akashi Therapeutics, Inc.'s top competitors are
Iovance Biotherapeutics, Inc.,
Myeloid Therapeutics,
River Road Investors,
Halo-Bio Rnai Therapeutics, Inc.,
Wave Life Sciences,
Triplet Therapeutics,
Ait Bioscience,
Audentes®,
Magenta Thinking,
Iwco.
Akashi Therapeutics, Inc.'s support email address is INFO@DARTRX.COM
Akashi Therapeutics, Inc.'s categories are Biotechnology Research
Akashi Therapeutics, Inc.'s founding year is 2010
